Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis
- 1 January 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 70 (1), 30-39
- https://doi.org/10.1093/cid/ciz156
Abstract
Background. Lung transplant recipients commonly develop invasive fungal infections (IFIs), but the most effective strategies to prevent IFIs following lung transplantation are not known. Methods. We prospectively collected clinical data on all patients who underwent lung transplantation at a tertiary care academic hospital from January 2007-October 2014. Standard antifungal prophylaxis consisted of aerosolized amphotericin B lipid complex during the transplant hospitalization. For the first 180 days after transplant, we analyzed prevalence rates and timing of IFIs, risk factors for IFIs, and data from IFIs that broke through prophylaxis. Results. In total, 156 of 815 lung transplant recipients developed IFIs (prevalence rate, 19.1 IFIs per 100 surgeries, 95% confidence interval [CI] 16.4-21.8%). The prevalence rate of invasive candidiasis (IC) was 11.4% (95% CI 9.2-13.6%), and the rate of non-Candida IFIs was 8.8% (95% CI 6.9-10.8%). First episodes of IC occurred a median of 31 days (interquartile range [IQR] 16-56 days) after transplant, while non-Candida IFIs occurred later, at a median of 86 days (IQR 40-121 days) after transplant. Of 169 IFI episodes, 121 (72%) occurred in the absence of recent antifungal prophylaxis; however, IC and non-Candida breakthrough IFIs were observed, most often representing failures of micafungin (n = 16) and aerosolized amphotericin B (n = 24) prophylaxis, respectively. Conclusions. Lung transplant recipients at our hospital had high rates of IFIs, despite receiving prophylaxis with aerosolized amphotericin B lipid complex during the transplant hospitalization. These data suggest benefit in providing systemic antifungal prophylaxis targeting Candida for up to 90 days after transplant and extending mold-active prophylaxis for up to 180 days after surgery.Funding Information
- Health Resources and Services Administration
- Transplant Infectious Disease Interdisciplinary Research Training (5T32AI100851)
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01-AI73896, P01-AI04533, R01-AI93257), K23-AI52222, K24-AI072522))
- Lediant Pharmaceuticals
- Cidara Pharmaceuticals
This publication has 46 references indexed in Scilit:
- Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole ProphylaxisClinical Infectious Diseases, 2017
- Is universal antifungal prophylaxis mandatory in adults after lung transplantation? A review and meta‐analysis of observational studiesClinical Transplantation, 2016
- Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized PatientsAntimicrobial Agents and Chemotherapy, 2016
- Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosisExpert Review of Anti-infective Therapy, 2013
- Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10‐year, single‐center experienceTransplant Infectious Disease, 2013
- Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug MonitoringAntimicrobial Agents and Chemotherapy, 2012
- Invasive Fungal Infections in Lung Transplant Recipients Not Receiving Routine Systemic Antifungal Prophylaxis: 12‐Year Experience at a University Lung Transplant CenterPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011
- Impact of Mold Infections in Explanted Lungs on Outcomes of Lung TransplantationTransplantation, 2010
- Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered AgentsClinical Infectious Diseases, 2009
- Variation in antifungal prophylaxis strategies in lung transplantationTransplant Infectious Disease, 2006